Showing 4411-4420 of 8202 results for "".
- And the Winners Are...Newsweek Names America’s Top Dermatologistshttps://practicaldermatology.com/news/and-the-winners-arenewsweek-names-americas-top-dermatologists/2461226/Newsweek has released the 2022 America‘s Best Dermatologists List in partnership with Statista. The list is split into two categories: cosmetic and medical and includes 275 dermatologists (125 cosmetic and 150 medical), many of whom sit on Practical Dermatology® and sister pub
- FDA Approves Dupixent for Children 6 Months to 5 Years with Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis/2461224/The FDA has approved Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab) for children aged 6 months to 5 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Regu
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a
- Message from ASLMS President Dr. Paul M. Friedmanhttps://practicaldermatology.com/news/message-from-aslms-president-dr-paul-m-friedman/2461221/Dr. Paul M. Friedman, president of the American Society for Laser Medicine and Surgery (ASLMS), is calling on members to expand philanthropic programs that can help change lives with lasers. “In the coming year, I will be looking to the membership to bring their talents forwa
- Cynosure Upgrades PicoSure System with PicoSure Pro Devicehttps://practicaldermatology.com/news/cynosure-upgrades-picosure-system-with-picosure-pro-device/2461220/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. An FDA-cleared 755nm picosecond laser, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide safe and effec
- FDA Accepts sBLA for Priority Review for Dupixent in PNhttps://practicaldermatology.com/news/fda-accepts-sbla-for-priority-review-for-dupixent-in-pn/2461218/FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) from Sanofi and Regeneron to treat adults with prurigo nodularis. The target action date for the FDA decision is September 30, 2022. The sBLA is supported by dat
- Timber's Topical Isotretinoin Gets Breakthrough Therapy Designation for CIhttps://practicaldermatology.com/news/timbers-topical-isotretinoin-gets-breakthrough-therapy-designation-for-ci/2461217/TMB-001, a topical isotretinoin formulated using patented IPEG™ delivery system from Timber Pharmaceuticals, Inc. has been granted Breakthrough Therapy designation by FDA for the treatment of congenital ichthyosis (CI). Timber is developi
- Lullage Launches in US on International Skin Pigmentation Dayhttps://practicaldermatology.com/news/lullage-launches-in-us-on-international-skin-pigmentation-day/2461213/Lullage, known as Bella Aurora in Europe and Asia, celebrates International Skin Pigmentation Day to raise awareness about the prevalence of skin pigmentation conditions and the
- 2022 Monkeypox Outbreak: Here’s What Dermatologists Need to Knowhttps://practicaldermatology.com/news/2022-monkeypox-outbreak-heres-what-dermatologists-need-to-know/2461210/As case counts of monkeypox cases increase in Europe and other parts of the globe including the US, dermatologists may have an important role to play in terms of making differential diagnoses. George Han, MD a dermatologist at Lenox Hill Hospital in New York City, spoke to Practical
- FDA Approves Dermavant's Vtama for Psoriasishttps://practicaldermatology.com/news/fda-approves-dermavants-vtama-for-psoriasis/2461205/FDA has approved Vtama® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist from Dermavant for the topical treatment of plaque psoriasis in adults. Vtama cream is the first and only FDA-approved steroid-free topical medication in its class.